ANZCTR search results

Insomnia is a common disorder managed in Australian general practice. Insomnia can be effectively treated with online cognitive and behavioural therapy for insomnia (CBTi), which leads to long-lasting insomnia improvements. We aim to provide Australian GPs with access to an online CBTi program (Sleepio) to treat insomnia and reduce dependence on sleeping pills over time. It is hypothesised that patients referred to this trial of Sleepio will experience improved insomnia symptoms, and reduced sleeping pill use over time.

Diet remains a cornerstone of type 1 diabetes (T1D) management, with carbohydrate intake having the greatest impact on insulin requirements and blood glucose fluctuations. However, there is limited scientific evidence comparing the effect(s) of different levels of carbohydrate intake on T1D management. A T1D outpatient centre in Perth WA has been actively implementing carbohydrate-focused diet interventions, including low-carbohydrate diets, for T1D. This presents an opportunity to conduct a chart review to better understand the effect(s) of varying levels of carbohydrate on T1D management outcomes, and to identify and describe effective dietary approaches for this clinical population. We expect that low-carbohydrate diets (<130 g/day) will lead to improvements in T1D management due to reduced error rates in calculating exogenous insulin requirements.

Our team will develop and test an online forum, MS JobSeek, led by employed peers with multiple sclerosis and overseen by a health psychologist. The peers share their work experiences and help to motivate and encourage persons with MS to explore work and study options. This group coaching and mentoring is supplemented with educational material to help users better understand the current job market. To maximise reach and quality of access we will deliver this targeted support and mentoring via the internet. We will examine whether MS JobSeek is effective in supporting return-to-work progression for persons with relapsing remitting or progressive multiple sclerosis using a rigorous scientific study design. The findings will help to generate new evidence on how job-seekers with multiple sclerosis engage with, and respond to, peer mentoring. We also hope to provide a framework for how peer support services might be run and optimised in vocational care.

ENDOR combination therapy is a natural alternative to steroid use, in the treatment of eczema and psoriasis. ENDOR Dermatitis Care Capsules contain multivitamins and other natural anti-inflammatory ingredients such as curcumin and ENDOR 3.5 cream is a soothing, moisturizing cream. This clinical trial will assess the effectiveness and safety of ENDOR Combination Therapy (ENDOR 3.5 cream and ENDOR Dermatitis Care Capsules) in treating moderate atopic dermatitis or psoriasis. A total of 60 participants will be recruited, and will use ENDOR Combination Therapy for sixty days. During the study, site personnel will assess their skin conditions, take progress photographs and administer questionnaires to assess quality of life. 20% of participants will be allocated to the placebo arm, and will be receiving dummy treatment. These patients will be offered the opportunity to trial ENDOR Combination Therapy at the end of the study if interested.

This pilot trial seeks to investigate the adherence rates and efficacy of an internet-delivered for repetitive negative thinking immediately following treatment and at 1-month follow-up.

The purpose of this study is to test the impact of medicinal cannabis on quality of life and symptoms in people with advanced cancer. Who is it for? You may be eligible for this study if you are aged 18 or over, have advanced cancer and a life expectancy of at least 2 months. Study details Two-thirds of the participants in this study will receive medicinal cannabis, while the other one-third will receive placebo. Both are oils taken by mouth, initially once a day, then increasing to a maximum of 3 times a day. The dose will be increased until symptoms are adequately controlled, then maintained for up to one month. After the trial period is completed, participants will be able to access medicinal cannabis via compassionate access. All participants will provide blood samples and answer questionnaires. We would also like your carer to be involved, if you have one. It is hoped this preliminary study will provide useful information about the risks and benefits of this formulation of medicinal cannabis, and how cannabis is metabolised by the body.

This study will determine the pharmacokinetic properties of Deflexifol, as well as test the safety and efficacy of Deflexifol when given as a bolus followed by infusion to patients that have failed standard of care Who is it for? You may be eligible to join this study if you are aged 18 and above and have metastatic or locally advanced malignancy for which standard of care treatment has failed. Study details Participants in this study are allocated to one of 4 dose levels of Deflexifol, administered to participants in a combined bolus and infusion. Patients will receive 6 cycles of one dose level, with one treatment occurring every 2 weeks. Pharmacokinetics will be measured during the first 2 cycles, and safety will be assessed every 2 weeks over the 6 cycles of treatment. A follow up visit will be conducted 30 days after the last dose of trial treatment. It is hoped this trial will determine a suitable dose for further study of Deflexifol in a phase II trial.

The purpose of the Walter and Eliza Hall Institute Stafford Fox Rare Cancer Program is to use blood, tumour tissue and eyebrow hair samples from patients with rare cancers to study these types of cancers in detail. Who is it for? You may be eligible for this study if you have cancer that is considered rare, occurring in less than 6 people for every 100,000 diagnosed per year. There are literally hundreds of different types of rare or less common cancers. In fact most cancers, except breast, prostate, bowel, lung and skin melanoma, can be considered rare or less common. Examples are soft tissue cancers (sarcomas), brain tumours, cervical cancers, thyroid cancers, liver cancers, testicular cancers and many more. The researchers are also interested if a person has had three or more different types of cancers in their lifetime. Study details By consenting to this study, all participants may choose to donate suitable tissue (blood, tumour tissue and eyebrow hairs) for analysis which will help us to better understand the biology driving the development of their rare cancer/s. Participants in this study will then be contacted by their research doctor on a regular basis (every six-twelve months) to ask about their general health for up to 5 years. We hope that in doing these analyses, novel regulatory mechanisms could be discovered which will allow more effective treatments to be developed.

The purpose of this study is to compare the currently used IV pole and pump to a smaller, portable IV pump, called a CADD pump, for the administration of IV antibiotics and IV fluids. You may be eligible for this study if you are aged 18 years or over and are a cancer inpatient who has been prescribed intravenous antibiotics or fluids. Participants in this study will be randomised by chance (like flipping a coin) into two groups. One group will use the CADD pump to receive their IV antibiotics/fluids, and the other group will use the existing IV pole and pump system. All participants will wear a step-counter, called an accelerometer, on their wrist. Patients will be asked to consent to the study by a research nurse and will be required to answer some brief questionnaires during their involvement in the study. It is hoped this research will show that the CADD pump helps inpatients to be more mobile in hospital, and that this will lead to improved patient outcomes and reduced hospital-acquired complications.

To determine if treatment of OSA during pregnancy, with CPAP or positional therapy, leads to improvement in clinical outcomes, particularly gestational diabetes. Pregnant women with any OSA, will be eligible to participate in the randomised trial, and will be randomized into three groups to be treated with Continuous Positive Airway Pressure (CPAP), Positional therapy and usual care. The primary outcome for this study is the incident gestational diabetes mellitus on oral glucose tolerance test (OGTT) performed at or prior to 28 weeks gestation